Spebrutinib besylate

SI-5191

Spebrutinib besylate, >98% (HPLC)

CAS No. : [1360053-81-1]

MDL No. : MFCD26142937

Synonyms : AVL-292 benzenesulfonate; CC-292 besylate

IUPAC Name : N-(3-((5-Fluoro-2-((4-(2-methoxyethoxy)phenyl)amino)pyrimidin-4-yl)amino)phenyl)acrylamide benzenesulfonate

Price And Availability
Pack Size	Price in USD	Add To Shopping Cart	Availability	Shipping Status
10MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
25MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
50MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
100MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
250MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
500MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026

Applications : Spebrutinib besylate is a covalent, orally active, and highly selective BTK inhibitor with IC50 of <0.5 nM, displaying at least 1400-fold selectivity over the other kinases assayed. Spebrutinib was under clinical development for the treatment of rheumatoid arthritis (phase II) and B-cell Lymphoma (phase I).

References : Evans E. K et al. J. Pharmacol Exp Ther., 346(2), 219-28, 2013.

Storage : Keep container tightly closed under nitrogen or argon and refrigerate for long-term shelf life.

Caution : In case of contact with skin or eyes, rinse immediately with plenty of water and seek medical advice. Wear suitable protective clothing and gloves.